Drive Wealth Management LLC purchased a new stake in shares of BioVie Inc. (NASDAQ:BIVI – Free Report) during the 4th quarter, Holdings Channel reports. The fund purchased 60,000 shares of the company’s stock, valued at approximately $120,000.
Separately, Sanders Morris Harris LLC purchased a new stake in BioVie during the 4th quarter valued at $85,000. Institutional investors and hedge funds own 4.59% of the company’s stock.
BioVie Stock Performance
NASDAQ:BIVI opened at $1.81 on Wednesday. The stock’s fifty day moving average is $2.44 and its 200 day moving average is $2.19. BioVie Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $33.10. The firm has a market capitalization of $32.16 million, a PE ratio of -0.16 and a beta of 0.49.
BioVie Profile
BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
Recommended Stories
- Five stocks we like better than BioVie
- Canada Bond Market Holiday: How to Invest and Trade
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- How to Calculate Stock Profit
- What Does the Future Hold for Eli Lilly?
- What is a Bond Market Holiday? How to Invest and Trade
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Want to see what other hedge funds are holding BIVI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioVie Inc. (NASDAQ:BIVI – Free Report).
Receive News & Ratings for BioVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioVie and related companies with MarketBeat.com's FREE daily email newsletter.